Identification of a new pharmacological activity of the phenylpiperazine derivative naftopidil: tubulin-binding drug

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of chemical biology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s12154-014-0122-0PMID 25584077PMCID PMC4286570
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oral Naftopidil Suppresses Human Renal-Cell Carcinoma by Inducing G1 Cell-Cycle Arrest in Tumor and Vascular Endothelial Cells

  2013influential reference
• Target proteins of ganoderic acid DM provides clues to various pharmacological mechanisms

  2012cited by this paper
• Naftopidil, a Selective α1-Adrenoceptor Antagonist, Suppresses Human Prostate Tumor Growth by Altering Interactions between Tumor Cells and Stroma

  2011influential reference
• A Prospective, Randomized, Controlled, Multicenter Study of Naftopidil for Treatment of Male Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: 75 mg Once Daily in the Evening Compared to 25 mg Thrice Daily

  2010cited by this paper
• Antivascular Actions of Microtubule-Binding Drugs

  2009cited by this paper
• Evidence that androgen-independent stromal growth factor signals promote androgen-insensitive prostate cancer cell growth in vivo.

  2009cited by this paper
• Naftopidil, a selective α‐1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest

  2008influential reference
• Development of novel magnetic nano-carriers for high-performance affinity purification.

  2008cited by this paper
• Thiazolidinedione anti-cancer activity: Is inhibition of microtubule assembly implicated?

  2007cited by this paper
• [Latest frontiers in pharmacotherapy for benign prostatic hyperplasia].

  2006cited by this paper
• Current state of the art of new tubulin inhibitors in the clinic.

  2006cited by this paper
• Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: A prospective, randomized controlled study

  2006cited by this paper
• Double blockade of cell cycle progression by coptisine in vascular smooth muscle cells.

  2005cited by this paper
• Antiangiogenic and Vascular-Targeting Activity of the Microtubule-Destabilizing trans-Resveratrol Derivative 3,5,4′-Trimethoxystilbene

  2005cited by this paper
• Microtubules as a target for anticancer drugs

  2004cited by this paper
• α1-Adrenergic Receptors and Their Inhibitors in Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia

  2004cited by this paper
• Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia.

  2004cited by this paper

• CAMK2G in subcellular Ca2+ homeostasis: Molecular mechanisms and therapeutic targeting.

  2025cites this paper
• A Perspective on the Permeability of Cocrystals/Organic Salts of Oral Drugs.

  2024cites this paper
• Solubility of naftopidil in pure and mixed solvents at 273.15–313.15 K and its correlation with the Jouyban-Acree and CNIBS/R-K models

  2020cites this paper
• Drug Repositioning of the α1-Adrenergic Receptor Antagonist Naftopidil: A Potential New Anti-Cancer Drug?

  2020cites this paper
• Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib

  2020cites this paper
• Naftopidil Molecular Salts with Improved Dissolution and Permeation

  2020cites this paper
• Loss of Fibroblast-Dependent Androgen Receptor Activation in Prostate Cancer Cells is Involved in the Mechanism of Acquired Resistance to Castration

  2019cites this paper
• Identification of HUHS190, a human naftopidil metabolite, as a novel anti-bladder cancer drug.

  2019cites this paper
• Interleukin‐6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation

  2018cites this paper
• A prospective randomized controlled study on the Suppression of Prostate Cancer by Naftopidil (SNAP)

  2018cites this paper
• Predicting the tumorigenic phenotype of human bladder cancer cells by combining with fetal rat mesenchyme.

  2018cites this paper
• Add-on Therapy With the α-Blockers Tamsulosin and Naftopidil Improves Voiding Function by Enhancing Neuronal Activity in Prostatic Hyperplasia Rats

  2018cites this paper
• Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate cancer cells

  2017cites this paper
• N-Heterocyclic (4-Phenylpiperazin-1-yl)methanones Derived from Phenoxazine and Phenothiazine as Highly Potent Inhibitors of Tubulin Polymerization.

  2017cites this paper
• Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells

  2017cites this paper